These improvements were accompanied by a significant modulation of key hepatic signaling pathways: the expression of pro-fibrotic ROCK1 and lipogenic SREBP-1c was suppressed, while the metabolic regulator AMPK was upregulated in the treated groups compared to the MetS group. Here, SREBF1 is linked to metabolic syndrome.